Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report

BackgroundThe treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia....

Full description

Saved in:
Bibliographic Details
Main Authors: Elisa Dinoi, Giuseppe Daniele, Angela Michelucci, Fulvia Baldinotti, Fabrizio Campi, Piero Marchetti, Stefano Del Prato, Angela Dardano
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Endocrinology
Subjects:
Prader-Willi syndrome
obesity
type 2 diabetes mellitus
GLP-1 RA
semaglutide
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1533209/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1533209/full

Similar Items